Gene · 9782
MATR3: matrin 3
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. MATR3: matrin 3. Genes, record 9782. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9782
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P43243 | Matrin-3 | 847 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents83
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 52716 | P43243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 52717 | P43243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 52727 | P43243 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7855 | P43243 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7950 | P43243 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 8367 | P43243 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 8369 | P43243 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 8371 | P43243 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 8374 | P43243 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15261 | P43243 | Espacenet |
1 to 10 of 83
See all 83 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,098
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MATR3 papers | Newest fiscal year |
|---|---|---|---|
| R01NS097542 | RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration | 6 | 2025 |
| ZIAAG000933 | Genetic etiology of Amyotrophic Lateral Sclerosis | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA077598 | Cancer Center Support Grant | 4 | 2025 |
| R01DK018477 | Enhancer Connectomes in Regulation of Gene Expression | 4 | 2025 |
| U54NS092091 | Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) | 4 | 2025 |
| ZIACP010121 | Molecular Epidemiology Studies of Occupational and Environmental Exposures | 4 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
| P50CA217694 | SPORE in Soft Tissue Sarcoma | 3 | 2025 |
| R01AG031867 | Protein aggregation in inclusion body and myofibrillar myopathies | 3 | 2025 |
1 to 10 of 1,098Source NIH's project files
See all 1,098 nih grantsPapers1,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MATR3 is essential for oocyte growth and maturation quality through a dual molecular mechanism. | Elife | 2026 | 42765984 | PubTator, text mining | PubMed |
| MATR3 promotes proliferation and invasion of colon adenocarcinoma cells: bulk, single-cell transcriptomic analysis and experimental validation. | Transl Oncol | 2026 | 42743658 | PubTator, text mining | PubMed |
| Pervasive noise in human pre-mRNA splice site selection. | Mol Cell | 2026 | 42607686 | PubTator, text mining | PubMed |
| The EV-A71 RNA-binding protein Matrin 3 facilitates viral replication by stabilizing viral RNA via ZDHHC20-mediated palmitoylation. | Proc Natl Acad Sci U S A | 2026 | 42546198 | PubTator, text mining | PubMed |
| A 57-Year-Old Male With Behavioral Variant Frontotemporal Dementia and MATR3 and NOS3 Mutations. | Ann Clin Transl Neurol | 2026 | 42374607 | PubTator, text mining | PubMed |
| Modification of internal RNA domains from the long non-coding RNA XIST refines roles in silencing and heterochromatin recruitment. | Hum Mol Genet | 2026 | 41926242 | PubTator, text mining | PubMed |
| RNA binding as an emerging regulatory dimension in the type I IFN response. | Cell Rep | 2026 | 41904951 | PubTator, text mining | PubMed |
| A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms. | PLoS Biol | 2026 | 41875078 | PubTator, text mining | PubMed |
| A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer. | Breast | 2026 | 41863200 | PubTator, text mining | PubMed |
| MATR3 regulates METTL3-Mediated m6A modification of MSI2 mRNA to activate the Wnt/β-Catenin pathway, exacerbating myocardial fibrosis and atrial fibrillation. | J Bioenerg Biomembr | 2026 | 41849072 | PubTator, text mining | PubMed |
1 to 10 of 1,420
See all 1,420 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9782
GET https://conductscience.org/api/genes/v1/9782/patents?page=2